VCM
AVXL icon

Versant Capital Management’s Anavex Life Sciences AVXL Stock Holding History

Versant Capital Management’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-417
Closed -$1.28K – 2758
2026
Q1 		$1.28K Buy
+417
New +$1.81K ﹤0.01% 2625
2025
Q4 		– Sell
-1,484
Closed -$13.2K – 2652
2025
Q3 		$13.2K Hold
1,484
– – ﹤0.01% 1806
2025
Q2 		$13.7K Hold
1,484
– – ﹤0.01% 1736
2025
Q1 		$12.7K Hold
1,484
– – ﹤0.01% 1597
2024
Q4 		$15.9K Buy
+1,484
New +$11.4K ﹤0.01% 1145

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Versant Capital Management's AVXL Position: Q2 2026 in Review

Versant Capital Management sold out of Anavex Life Sciences (AVXL) in Q2 2026, closing a stake of 417 shares — an estimated $1.28K sold.

Versant Capital Management first reported a position in AVXL in Q4 2024 and held it in 5 quarters. The position peaked at $15.9K in Q4 2024. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • Versant Capital Management reported no remaining Anavex Life Sciences position as of Q2 2026 after selling out during the quarter.
  • Versant Capital Management sold 417 Anavex Life Sciences shares in Q2 2026, an estimated $1.28K.
  • Versant Capital Management first reported a position in Anavex Life Sciences in Q4 2024 and held it in 5 quarters.
  • Versant Capital Management's Anavex Life Sciences position peaked at $15.9K in Q4 2024.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.